Two-year contract is to supply medical isotopes produced at Nordion’s Vancouver and Ottawa facilities
OTTAWA—Nordion Inc. has inked a two-year contract with Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a diagnostic imaging business company. The contract is to supply strontium-82, a cyclotron based medical isotope produced both at Nordion’s Vancouver and Ottawa facilities.
“Bracco is committed to support the worldwide supply of strontium today and in the future,” said Vittorio Puppo, president and CEO of Bracco Diagnostics, Inc. “To this end, the agreement with Nordion is an important part of Bracco’s success and growth in nuclear medicine imaging.”
Strontium-82 is used in CardioGen-82 generators and over time decays into an injectable medical isotope called Rubidium-82. CardioGen-82 is a closed system used to produce Rubidium-82 chloride injection for intravenous administration. Rubidium Rb82 chloride injection is indicated for positron emission tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.
“We believe that partnerships, like this one with Bracco Diagnostics, are imperative in bringing advanced imaging solutions to patients,” said Tom Burnett, general manager of Medical Isotopes, Nordion Inc.